Pharma industry’s success will be measured by cost of medicines at home

pharma industry
India’s pharma industry's success rests on affordable generics for foreign markets, but keeping essential medicines in stock at public clinics is a separate policy challenge.

Pharma industry’s success will be measured by cost of medicines at home: India has many titles, but few are used as proudly as “the pharmacy of the world.” Its pharmaceutical industry has earned a reputation for supplying affordable generic medicines and vaccines around the world. A government update in September showed how much work remains to secure the inputs that sustain that achievement. By June 2026, 39 projects under the Centre’s bulk-drug incentive scheme had been commissioned.

China still accounted for nearly three-quarters of the value of India’s imports of bulk drugs, active pharmaceutical ingredients and drug intermediates in 2024–25. Reducing that exposure would make production more secure. India faces a further challenge at home, where many households still pay for essential medicines out of their own pockets.

READ | Trump’s generic drug tariffs threaten India’s pharma trade

How India got its edge in generic medicines

India’s pharmaceutical competitiveness developed over time, helped by relatively low labour costs, a skilled workforce and large-scale production. The Patents Act of 1970 was particularly important. For medicines, it allowed firms to patent a manufacturing process while leaving other firms free to make the same drug by a different process. Indian companies could therefore produce medicines patented elsewhere by developing their own methods. That helped lay the foundations of the generics industry.

India joined the World Trade Organization in 1995 and introduced pharmaceutical product patents in 2005 to meet its obligations under the TRIPS agreement. For drugs covered by Indian product patents, developing a different manufacturing process was no longer enough. The new rules gave firms greater reason to invest in research and development. The skills and production capacity they had built under the earlier regime remained an advantage.

READ | UK-India pharma corridor links British research with Indian scale

The dependence the pandemic exposed

The pandemic showed how quickly a disruption in supplies from abroad could affect Indian drugmakers. In March 2020, the government restricted exports of 13 active pharmaceutical ingredients and formulations made from them. The list included paracetamol, progesterone and vitamin B12. India subsequently eased the restrictions. The episode showed the limits of using export controls to protect domestic supplies. Restrictions could conserve stocks in the short term, with consequences for countries that bought medicines from India. They did little to restore the flow of ingredients Indian factories needed.

The government approved the ₹6,940 crore production-linked incentive scheme for bulk drugs in 2020. By June 2026, 39 of the 48 approved projects had been commissioned, covering 28 drug ingredients and starting materials. These plants give buyers more options for some critical inputs. The next test is whether they can supply those inputs consistently and at prices that Indian drugmakers can absorb. For companies competing on the price of finished medicines, a reliable domestic source is most useful when it can also compete on cost.

READ | Pharma market growth shifts to chronic care

Pharma industry: Why affordable medicines remain out of reach

The National Health Accounts put out-of-pocket spending at 43.4% of India’s total health expenditure in 2022–23, down from 64.2% in 2013–14. That figure covers healthcare as a whole. For households that buy medicines every month, affordability also depends on whether the prescribed drug is stocked at a public facility or must be bought from a private pharmacy. India’s ability to produce affordable generics for world markets is of limited help to a patient who has to pay repeatedly for a prescription the public system could have filled.

Export markets offer substantial commercial opportunities once a company has invested in meeting regulatory requirements. North America was India’s largest pharmaceutical export region in 2024–25, with Europe second. At home, the Drugs (Prices Control) Order sets ceiling prices for scheduled formulations. These conditions can affect where a firm chooses to invest, although export figures alone tell us little about which medicines are available to Indian patients. A price ceiling can reduce what a patient pays for a listed drug. Keeping the drug on the shelf at a public clinic depends on procurement and distribution.

Keeping essential medicines in stock

The National Health Mission already supports the provision of free essential medicines at public facilities. States can make better use of that programme by buying against estimates of actual need and tracking stock at individual facilities. Where patients need regular treatment, any expansion of insurance should also consider the prescriptions they have to fill between hospital visits.

For a patient taking medicines for diabetes or high blood pressure, the practical test comes at the next refill. A public clinic that can reliably fill that prescription saves the patient a trip to a private pharmacy and a bill that would otherwise come due again the following month.

Sree Lasya Tadikonda is an economics student at Manipal Academy of Higher Education, Bengaluru.

READ | Pharmaceutical industry risks rise amid US tariff threat